No NASDAQ problem - comma is key - 550 shareholders with 1.1 M share volume over past year - so active accounts with average 2k shares traded in past year. Easy.

“Vagal Nerve Stimulus-VNS altered the strengths and patterns of correlations among brain networks relative to those in the resting state. The most notable changes in network-network interactions were related to the limbic system. Together, such profound and widespread effects of VNS may underlie its unique potential for a wide range of therapeutics to relieve central or peripheral conditions.”

https://www.biorxiv.org/content/10.1101/200220v2

ECOR has the right tool at the right time. My Migraine patients are amazed-as I am.

Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus

https://www.biorxiv.org/content/10.1101/2020.02.12.945576v1

“After the 2019-nCoV infection, CD4+T lymphocytes are rapidly activated to become pathogenic T helper (Th) 1 cells and generate GM-CSF etc. The cytokines environment induces inflammatory CD14+CD16+ monocytes with high expression of IL-6 and accelerates the inflammation. These aberrant and excessive immune cells may enter the pulmonary circulation in huge numbers and play an immune damaging role to causing lung functional disability and quick mortality. Our results demonstrate that excessive non-effective host immune responses by pathogenic T cells and inflammatory monocytes may associate with severe lung pathology. Therefore, we suggest that monoclonal antibody that targets the GM-CSF may potentially curb immunopathology caused by 2019-nCoV and consequently win more time for virus clearance.”

HGEN has the answer - Fauci knows.

electroCore to Participate in Three Upcoming Virtual Investor Conferences


July 09, 2020 16:01 ET | Source: electroCore
BASKING RIDGE, N.J., July 09, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that Dan Goldberger, Chief Executive Officer, will participate in three upcoming investor conferences:

Maxim Group/M-Vest COVID-19 Virtual Conference Series: Re-Engaging Medical Practices in an Era of COVID-19
Format: panel discussion
Date: Thursday, July 16
Panel 2, “Can’t Touch This! – Time for These Devices to Shine!”
Time: 12:30pm – 1:45pm ET

To access the panel discussion, please RSVP HERE

Zooming with LD Micro
Format: corporate presentation followed by 1x1 virtual investor meetings
Date: Tuesday, July 21
Time: 8:00am – 8:40am PT

Investors can register for the presentation HERE.

Canaccord Genuity 40th Annual Growth Conference
Format: 1x1 virtual investor meetings
Date: Tuesday, August 11

Asia, Australia, South America- An HGEN EU foothold will be announced ASAP.

Remdesivir was Fauci’s Big Therapeutic Hope - HGEN’s Lenzilumab has Next: https://www.cnsnews.com/article/national/bailey-duran/potential-covid-19-therapy-lenzulimab-chosen-nih-big-effect-trial

ECOR Jumped to $3 and $4 on last two conference PRs -today is 3rd - best yet - Canaacord - the world hears about Gammacore for COVID 19 lung disease - Ameritrade followup with CMO already scheduled to further disseminate!

ECOR at Canaacord Genuity Growth Conference TODAY - don’t know the time - anyone?

“On July 27, HGEN announced that lenzilumab had been selected by NIAID for the Big Effect Trial (BET). Lenzulimab will be tested in combination with remdesivir in 200 COVID-19 patients compared to remdesivir alone. This trial will build on the initial NIAID trial that led to the emergency use authorization of remedesivir, which remains one of the few available treatment options for COVID-19”

https://www.cnsnews.com/article/national/bailey-duran/potential-covid-19-therapy-lenzulimab-chosen-nih-big-effect-trial

That’s a good Bet on B.E.T.

120K Shares

Brazil ensures no HGEN Phase 3 delay.

NeuroCovid from lung and GI tract to brain - via Vagus Nerve- HGEN restricts spread through Gammacore electric therapy.

Now own 120K on CEO’s “Multibillion Dollar Additional Targets” - I’ve learned to respect his guidance since 80 cents price per share.

Now own 120K on CEO’s “Multibillion Dollar Additional Targets” - I’ve learned to respect his guidance since 80 cents price per share.

HGEN CEO @ BTIG - “The last thing we are oz Complacent - We’ll Launch Lenz by EIY for COVID19”

HGEN CMO - Lenz given over 1 day Rem given over 5-10 days !

Added another 10K HGEN ahead of CEO slipping MAYO Additional Data Publication - about which he’s “Very Excited” - c’mon man!

Fauci changed Remdesivir’s Primary endpoint by this point in the Gammacore trial but the two Primary Investigators studying ECOR’s COVID Treatment haven‘t-Need for mechanical ventilation is the gold standard in COVID ARDS. If Either study positive- an immediate EUA will be issued.

The President of the Spanish Neuromodulation Society is Running a 90 patient open labeled trial of
ECOR Gammacore with the primary endpoint of “Need for mechanical ventilation” - a stronger endpoint than Remdesivir- and it has passed the interim DMC futility Evaluation- he’s presenting this at the annual meeting in September - https://clinicaltrials.gov/ct2/show/NCT04368156?term=Gammacore+Spain&draw=2&rank=1
Are you kidding me with this price action ? Just added again.

On ECOR Gammacore “The non-invasive devices are relatively new, but when used in the clinical setting they could reduce patient risk of potential complications due to surgical implantation of the device. I do not recommend the commercial VNS devices without doctor prescription and use monitoring....VNS devices could be a huge shift to treat these various conditions. All current medications come with side effects. If a device like this can improve your life and the way you function, it’s something worth researching and discussing with a doctor.“
https://www.brainfacts.org/diseases-and-disorders/therapies/2019/are-commercial-vagus-nerve-stimulation-devices-safe-and-effective-042419

“They Got a Lot of COVID in Brazil”

https://www.humanigen.com/press/Humanigen-Expands-Phase-III-Study-of-Lenzilumab-in-COVID-19-to-Brazil

COVID ARDS Air Hunger leads to PTSD

https://scholar.google.com.hk/scholar?hl=en&as_sdt=0%2C33&q=ARDS+air+hunger+and+pTSD&btnG=#d=gs_qabs&u=%23p%3DDf7jYhhVAKUJ

ECOR treats PTSD

https://www.medrxiv.org/content/10.1101/2020.02.10.20021626v3

COVID Trials Open Label - Big Pharma gets wind - still a rumor but one with teeth based on source. PFE-ECOR

Clinical administration of inhaled/IV recombinant GM-CSF (sargramostim) in pts w #COVID-19 In Trial NCT04326920- a randomised trial-administration of recombinant GM-CSF in ARDS did Not improve clinical outcome http://clinicaltrials.gov/show/NCT00201409… https://thelancet.com/journals/lanres/article/PIIS2213-2600(20)30267-8/fulltext… HGEN Has the Right Target - Block GM-CSF in ARDS.


https://clinicaltrials.gov/ct2/show/results/NCT00201409

CYDY a lesser Target - downstream

PFE has invested in Neuromodulation before -It acquired Neuronetics -the leader in the development of NeuroStar TMS Therapy (transcranial magnetic stimulation), a non-invasive form of neuromodulation.- An ECOR acquisition expands PFE into COVID Neuromodulation.

For those who think GMCSF is Needed for good pulmonary health:
“Cigarette smoke increased pulmonary GM-CSF and Alveolar macrophage proliferation, and chronically increased pulmonary GM-CSF recapitulated the cardinal features of Desquamative Interstitial Pneumonia including Alveolar Macrophage accumulation, emphysema, secondary polycythemia, and increased mortality in mice. These observations suggest pulmonary GM-CSF may be involved in the pathogenesis of Desquamative Interstitial Pneumonia”

https://scholar.google.com.hk/scholar?start=10&q=GM+CSF+receptor+targeting+and+pulmonary+proteinosis&hl=en&as_sdt=0,33&as_ylo=2020#d=gs_qabs&u=%23p%3DqVu2varfYaMJ

HGEN blocks GMCSF -reversing DIP.

ECOR “According to a paper in the Annals of the American Thoracic Society, research has shown that, among ICU survivors of COVID-19-related ARDS, the experience of “air hunger” (severe dyspnea) is often associated with post-traumatic stress disorder (PTSD).” https://www.rtmagazine.com/disorders-diseases/critical-care/icu-ventilation/covid-19-ards-dyspnea-ptsd/


“Transcutaneous Cervical Vagal Nerve Stimulation Reduces Sympathetic Responses to Stress in Posttraumatic Stress Disorder” https://www.medrxiv.org/content/10.1101/2020.02.10.20021626v3

Gammacore reduces sympathetic nervous system created stress and SARS2 spread to the Brainstem- both allowing greater ease of respiration. The body of Gammacore supportive data keeps growing.

ECOR Q1 earnings call - slowly increasing sales, significant increase in margins, boost from telehealth trend: “Paid months of therapy outside the U.S. in the first quarter of 2020 actually increased to 1,008 from 961 in the fourth quarter of 2019. Not surprisingly, the impact of the COVID-19 pandemic in the United Kingdom has put pressure on new patient starts, and that could affect our ability to grow revenue from the United Kingdom channel in the remainder of this year. Turning now to our U.S. commercial activities. In the pharmacy benefit management and commercial payer channels, our distribution partners report continued slow growth in paid months of therapy. We experienced sequential growth in the first quarter, and that trend appears to have continued into April 2020. This cadence is notable because late last year, we reallocated sales resources away from the commercial channel. It's too early to conclude that the commercial channel has turned a corner, but our recent announcement that we gained access to millions of ESI lives on a preferred basis is one potential driver of paid months of therapy. We'll provide a more comprehensive commercial update in August.... you're going to see gross margins continue to expand just with the arithmetic of higher volumes over the same fixed expense.... our virtual implementation of gammaCore therapy has been very, very well received. You're probably aware, but telehealth has been a technology initiative within the VA system for several years now, and it's really accelerated over the last 8 weeks because of the pandemic. And many of our hospital customers have really embraced the notion that a neurologist can do a telehealth consult with a patient and they can prescribe gammaCore therapy, and we can ship the therapy directly to the patient and train and in-service the patient in their home. The patient does not have to come into the facility at all. That's in contrast with other second and third-level therapies that are injections that have to be delivered by a health care professional. And so we've been able to move up in the continuum of care by virtue of the fact that we can completely leverage the telehealth platform that the VA system is so excited about”

From the Horse's Mouth - Business wire was a typo-10/11:


Humanigen to Present at the BTIG Virtual Biotechnology Conference 2020
August 5, 2020

Management presentation Monday, August 10 at 2:00 pm EDT



Burlingame, CA, August 5, 2020 – Humanigen, Inc., (HGEN) (“Humanigen”), announced today that Cameron Durrant, MD, MBA, Chief Executive Officer and Dale Chappell, MD, MBA, Chief Scientific Officer of Humanigen will present a company overview and business update at the BTIG Virtual Biotechnology Conference 2020 on Monday, August 10th, 2020 at 2:00 pm Eastern Time. The conference is being held in a virtual format.



A live webcast of the event can be accessed at https://www.humanigen.com/investor-materials.

Please watch the video for more on vagal stimulation (Gammacore etc) and the Brainstem - certainly This theory needs more work.

“Competition” spanked by FDA in AIDS - same in COVID 19-
CYDY -What a poorly run screw up company run by a con man - “ The FDA rejected CytoDyn’s application for its lead program, an antibody to treat HIV in combination with antiretroviral therapy, because it’s missing some information, the company announced Monday—two months after it revealed it had previously sent the wrong data sets to the agency”- Fiercebiotech
Only Phase 3 anti GN CSF company is HGEN - all other Targets Downstream and inferior.

“The percentages of GM-CSF-expressing CD4+ T cells, CD8+ T cells, natural killer cells and B cells were significantly higher in the blood of patients with COVID-19 who were admitted to an intensive care unit (ICU) than in healthy controls.”

https://www.nature.com/articles/s41577-020-0357-7?elqTrackId=801873428fb148a9b448f36eae558b8b

HGEN has the right target - see CMO’s comments about Knockout mice on BET Webcast replay- further supporting data.

Anyone’s “observations” regarding GM-CSF pale in importance to peer reviewed literature - CYDY’s CEO once observed that the Vietnamese trinkets he sold were in fact American Indian Artifacts- that’s why we value the review of our peers - not YouTube videos and Stock promoter PR. The paper I linked was published in Nature - one of the most respected medical research journals world wide. It clearly states that GM CSF is found to be elevated in those COVID patients with advanced disease - like the Severe to Critical patients HGEN is Studying - now with the same primary endpoint NIAID chose for Remdesivir in an attempt to compare like to like. This change will accelerate an EUA on interim data. The percentage of asymptomatic or Early COVID patients with elevated GMCSF Is unimportant and likely unknown in peer reviewed literature..

Pulmonary side effect due to blocking GMCSF receptor in all or none way - Too much blockage results in Dangerous side effect - so Mav- which does - has to be underdosed. Lenz his the ligand - can dose much higher safely - all good for HGEN.

Hey JB -GM-CSF is a solid predictor of severe-critical COVID-19 - much more (as CMO outlined in BET talk) than IL-6 or CYDY’s CCR5 or TNF-A etc- so HGEN has right target for its disease targeted- “ GM-CSF was recently noted as being upregulated in the serum of a subset of patients with COVID-19 (ref.73). It was reported that the percentages of GM-CSF-expressing CD4+ T cells, CD8+ T cells, natural killer cells and B cells were significantly higher in the blood of patients with COVID-19 who were admitted to an intensive care unit (ICU) than in healthy controls1. This pan-cellular observation was not seen with IL-6 and TNF expression in the respective populations. Furthermore, a GM-CSF+IFN?+CD4+ T cell signature, which is associated with GvHD31 and autoimmune arthritis26, encephalomyelitis74 and diabetes75, was found in the peripheral blood of the patients in the ICU. These T cell responses were accompanied by a significant increase in the numbers of CD14+CD16+ inflammatory monocytes, and a high percentage of monocytes secreted GM-CSF and IL-6 (ref.1). The reported immunological changes appeared to be more pronounced in patients admitted to an ICU than in those who did not require ICU care and thus appear to correlate with clinical severity. Similarly, a study in patients with sepsis demonstrated that an increased percentage of circulating GM-CSF-producing TH cells is predictive of poor outcome and is correlated with IL-1 and IL-6 expression; these cells exhibited a memory phenotype and were reported to be mediators of dysfunctional neutrophil activity38. However, given the role of GM-CSF in pathogen clearance and lung repair, it is important to consider that GM-CSF levels may be elevated as a compensatory mechanism or as a background consequence of increased COVID-19 severity. Further studies are therefore needed to determine whether increased production of GM-CSF in patients with COVID-19 represents a physiological response to infection or a pathogenic driver of disease.”
https://www.nature.com/articles/s41577-020-0357-7?elqTrackId=801873428fb148a9b448f36eae558b8b

Hi Karin - Have you seen this new proposed Mechanism of Action proposed for ECOR?

Targets SARS 2 Neuroinvasion And Respiratory Depression via Vagus Nerve- “Trafficking via the vagus nerve. It is well established that influenza virus (IV) infects the lungs and spreads to the brain via the retrograde axonal transport in the vagus nerve (46, 50). The vagus nerve travels through the neck and thorax to the stomach and it connects the lung to the gut and brain, also referred to as lung-gut-brain axis (51). Since the lungs represent a major reservoir of SARS-CoV-2 infection, at least in the early stages of COVID-19 disease, it is possible that SARS-CoV-2 could use the vagus nerve to enter the CNS and travel throughout the lung-gut-brain axis, potentially interfering with all of these systems at different time-points during infection. This may explain why some patients experience a combination of gastrointestinal, neurologic and lung symptoms throughout the course of infection”

https://onlinelibrary.wiley.com/doi/epdf/10.1111/ene.14442

This video explains how the origin off the vagus nerve- the Brainstem- can become infected with SARS which leads to respiratory depression during ARDS- another target for ECOR

https://www.google.com/amp/s/www.technologynetworks.com/biopharma/videos/amp/teach-me-in-10-the-vagus-nerve-and-covid-19-with-dr-paul-peter-tak-338311

I disagree- Lenz treats Cytokine chain up river of Leron ands is, therefore, the more potent agent- but don’t take my word for it - here’s an independent peer reviewed paper published in Nature -“Because GM-CSF can stimulate the expression of IL-1, IL-6, TNF and other pro-inflammatory cytokines and chemokines, a GM-CSF-targeting strategy might have broader effects than other immunomodulatory approaches when one is seeking to therapeutically dampen overactive immune responses”
https://www.nature.com/articles/s41577-020-0357-7?elqTrackId=801873428fb148a9b448f36eae558b8b

Gilead clearly chose Lenzilumab and Mavrilimumab (Targets GMCSF receptor vs ligand so dosing more restricted than is Lenz - ligand targeting) Over Leronlimab.

Tropical Storm Isaias came to NY this week and the two patients with a history of severe low barometric pressure related Migraines - who I treated with 3-4 days of ECOR Gammacore t.i.d. Prior to the storm- were comfortable with no supplemental migraine therapy required. I am impressed and they are thrilled.

Nice post -M&A is all I see....)))